We are live on ! Find out more
ABUS icon

Arbutus Biopharma
ABUS

80 hedge funds and large institutions have $79.4M invested in Arbutus Biopharma in 2020 Q4 according to their latest regulatory filings, with 28 funds opening new positions, 22 increasing their positions, 12 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

133% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 12

83% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 12

23% more funds holding

Funds holding: 65 → 80 (+15)

5% more capital invested

Capital invested by funds: $75.5M → $79.4M (+$3.9M)

2.87% less ownership

Funds ownership: 29.12% → 26.25% (-2.9%)

32% less call options, than puts

Call options by funds: $4.67M | Put options by funds: $6.87M

Holders
80
Holders Change
+15
Holders Change %
+23.08%
% of All Funds
1.42%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
28
Increased
22
Reduced
12
Closed
12
Calls
$4.67M
Puts
$6.87M
Net Calls
-$2.2M
Net Calls Change
-$1.83M

Top Buyers

1
BlackRock
BlackRock
New York
+$2.72M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$1.77M
3
Renaissance Technologies
Renaissance Technologies
New York
+$1.53M
4
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT)
United Kingdom
+$1.2M
5
Group One Trading
Group One Trading
Illinois
+$893K

Top Sellers

1
FCMI
Foresite Capital Management IV
California
-$10.4M
2
Morgan Stanley
Morgan Stanley
New York
-$5.21M
3
Goldman Sachs
Goldman Sachs
New York
-$682K
4
Deutsche Bank
Deutsche Bank
Germany
-$400K
5
Assenagon Asset Management
Assenagon Asset Management
Luxembourg
-$139K
Name Holding Trade Value Shares
Change 		Change in
Stake
Citadel Advisors
26
Citadel Advisors
Florida
$351K +$101K +28,731 +41%
VF
27
Virtu Financial
New York
$222K +$219K +62,530 New
Goldman Sachs
28
Goldman Sachs
New York
$210K -$682K -194,865 -77%
State Street
29
State Street
Massachusetts
$201K +$16.5K +4,700 +9%
Bank of New York Mellon
30
Bank of New York Mellon
New York
$200K +$135K +38,577 +217%
Citigroup
31
Citigroup
New York
$196K +$164K +46,724 +547%
CSS
32
Cubist Systematic Strategies
Connecticut
$181K +$178K +50,899 New
BFM
33
Boothbay Fund Management
New York
$168K +$119K +34,062 +258%
PCM
34
Prelude Capital Management
New York
$160K +$350 +100 +0.2%
EMG
35
ETF Managers Group
New Jersey
$154K -$14.3K -4,074 -9%
MFS
36
Mirabella Financial Services
United Kingdom
$143K -$44.2K -12,612 -24%
Jane Street
37
Jane Street
New York
$139K +$77.9K +22,239 +132%
AGM
38
Alpine Global Management
New York
$127K +$125K +35,825 New
OGC
39
One68 Global Capital
New York
$113K +$112K +31,880 New
WMA
40
Wealth Management Associates
New Jersey
$112K +$111K +31,570 New
MA
41
MYDA Advisors
New York
$107K +$105K +30,000 New
HF
42
HRT Financial
New York
$99K +$98.2K +28,054 New
Creative Planning
43
Creative Planning
Kansas
$95K +$93.5K +26,703 New
GCP
44
GSA Capital Partners
United Kingdom
$93K +$91.8K +26,221 New
Charles Schwab
45
Charles Schwab
California
$75K -$42K -12,000 -36%
CS
46
Credit Suisse
Switzerland
$68K +$67.1K +19,151 New
UBS Group
47
UBS Group
Switzerland
$64K +$38.2K +10,913 +156%
BFEC
48
Benjamin F. Edwards & Company
Missouri
$58K +$57.4K +16,400 New
Royal Bank of Canada
49
Royal Bank of Canada
Ontario, Canada
$55K +$5.24K +1,497 +11%
PTP
50
Platform Technology Partners
New York
$53K +$52.5K +15,000 New
1
2
3 4

ABUS Hedge Fund Activity: Q4 2020 in Review

80 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Arbutus Biopharma (ABUS) for Q4 2020, worth a combined $79.4M — up 5.2% from $75.5M a quarter earlier.

Buyers outnumbered sellers: 28 funds opened new ABUS positions and 12 closed out — a net gain of 16 holders — while 22 added to existing stakes and 12 trimmed.

The largest buyer was BlackRock, adding an estimated $2.72M. The largest seller was Foresite Capital Management IV, exiting entirely with an estimated $10.4M sold.

  • 80 institutional investors held Arbutus Biopharma (ABUS) as of Q4 2020, up from 65 in Q3 2020.
  • Funds reported $79.4M of Arbutus Biopharma stock for Q4 2020, up 5.2% quarter-over-quarter.
  • 28 funds opened new Arbutus Biopharma positions in Q4 2020 and 12 closed out, a net change of +16 holders.
  • The largest Arbutus Biopharma buyer in Q4 2020 was BlackRock, an estimated $2.72M added.
  • The largest Arbutus Biopharma seller in Q4 2020 was Foresite Capital Management IV, an estimated $10.4M sold.

Based on aggregated 13F filings for Q4 2020.